Literature DB >> 30785770

Tyrosine Kinase Inhibitor-associated Fibrothorax.

Andres M Adrianza1, Carlos A Jimenez1, Grecia L Aldana1, Leonardo Pozo1, Jorge E Cortes2, Ala Eddin S Sagar1.   

Abstract

Mesh：

Substances：

Year:  2019        PMID： 30785770      PMCID： PMC6543723          DOI： 10.1164/rccm.201806-1155IM

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN： 1073-449X            Impact factor:   21.405


× No keyword cloud information.
  3 in total

1.  Severe dyspnoea in a patient with chronic myelogenous leukaemia on a tyrosine kinase inhibitor.

Authors:  Celalettin Ustun; Nicole Randall; Eitan Podgaetz; Khalid Amin; H Erhan Dincer
Journal:  Thorax       Date:  2015-05-02       Impact factor: 9.139

2.  Lung abnormalities after dasatinib treatment for chronic myeloid leukemia: a case series.

Authors:  Anne Bergeron; Delphine Réa; Vincent Levy; Clément Picard; Véronique Meignin; Jérome Tamburini; Heriberto Bruzzoni-Giovanelli; Fabien Calvo; Abdellatif Tazi; Philippe Rousselot
Journal:  Am J Respir Crit Care Med       Date:  2007-06-28       Impact factor: 21.405

3.  Dasatinib-induced pleural effusion: Chylothorax, an option to consider.

Authors:  Lucía Ferreiro; Esther San-José; Juan Suárez-Antelo; Luis Valdés
Journal:  Ann Thorac Med       Date:  2016 Oct-Dec       Impact factor: 2.219
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.